5-HTP for Fibromyalgia

Verdict: Weak, unreplicated evidence; safety concerns

5-HTP may modestly ease fibromyalgia symptoms, but the case rests on two small, 30-year-old trials from a single research group with no modern replication, and no regulator or major clinic endorses it. Given documented serotonin-syndrome and historical EMS safety concerns, it should not replace proven fibromyalgia treatment.

C 🟠 C Weak Evidence Safety Review

🔬Why this grade7-layer evidence engine

The grade is C (weak evidence) because the entire human case rests on just two old, small studies from the same Italian group: a 1990 double-blind RCT (PMID 2193835, n=50) and a 1992 90-day open-label trial (PMID 1521674, n=50). Both reported significant improvement in tender points, pain, sleep, anxiety, and fatigue, but both are rated low quality, are over 30 years old, and have never been independently replicated by a modern RCT or meta-analysis.

No authority endorses 5-HTP for fibromyalgia. NIH ODS, Mayo Clinic, Cleveland Clinic, and Harvard Health do not recommend it for this condition, and ACR/EULAR guidelines exclude it, favoring exercise, CBT, and approved drugs such as duloxetine and pregabalin. The lack of any guideline backing keeps the grade from rising above C despite a biologically plausible serotonin-precursor mechanism.

A safety-review flag applies. The FDA states it cannot determine that oral dosage forms of L-Tryptophan and related compounds such as L-5-hydroxytryptophan can be safely used as dietary supplements, reflecting the historical eosinophilia-myalgia syndrome (EMS) link, and 5-HTP carries serotonin-syndrome risk when combined with SSRIs/SNRIs, drugs commonly used in fibromyalgia, so it should not replace evidence-based care.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.45
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Safety Review
Confidence
78%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.448
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome
PMID: 2193835 1990 RCT (double-blind) n = 50
Finding: All clinical parameters significantly improved with 5-HTP versus placebo; only mild, transient side-effects (specific p-values not in abstract).
🟠 Limited quality
View on PubMed
Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study
PMID: 1521674 1992 RCT (open-label) n = 50
Finding: All clinical variables showed significant improvement (P<0.001); good/fair improvement in ~50% of patients; side-effects in 30%, one withdrawal.
🟠 Limited quality
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA cannot determine that oral dosage forms of L-Tryptophan and related compounds such as L-5-hydroxytryptophan can be safely used as dietary supplements. source↗
L4d TW TFDA / 衛福部
Against
5-HTP在台灣並非合法的保健食品(食品)原料;色胺酸(L-tryptophan)則為合法之食品營養補充劑成分。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-fibromyalgia-INT-5-htp-001 繁體中文版 →